Left Atrial Reservoir Strain for Predicting Progression to End-Stage in Hypertrophic Cardiomyopathy
Clicks: 5
ID: 317578
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
1.2
/100
5 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #17 of 96 articles by views in European Heart Journal - Cardiovascular Imaging
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AIMS: End-stage hypertrophic cardiomyopathy (HCM), defined as a left ventricular (LV) ejection fraction (LVEF) < 50%, is associated with poor prognosis; however, predictors of progression remain unclear. We aimed to identify prognostic factors for progression to end-stage HCM. METHODS AND RESULTS: We analyzed 925 patients with HCM between 2007 and 2023 who underwent ≥1 year of follow-up echocardiography. The primary outcome was progression to end-stage HCM, defined as an LVEF <50% without reversible causes. A CMR subcohort included 491 patients with baseline CMR. During a median follow-up of 6.5 years (IQR: 3.3-10.7), 35 patients (3.8%) progressed to end-stage HCM (10-year cumulative incidence: 4.4%, 95% CI: 2.5-6.2%). LVEF, LV apical aneurysm, and LARS were independent predictors of progression to end-stage HCM (per 1% decrease in LARS: adjusted HR 1.10, 95% CI 1.04-1.17, p < 0.001), and impaired LARS (<16.9%) was associated with a higher risk. In the CMR subcohort, LARS remained an independent predictor after adjusting for late gadolinium enhancement (LGE%) (adjusted HR 1.11, 95% CI 1.02-1.20, p = 0.011). Adding LARS to a model including LVEF, LV apical aneurysm, and LA size yielded significant incremental prognostic value (global χ2 27.1 to 40.1; p < 0.001). Similar incremental value was observed in models including LGE% in the CMR subcohort. After progression to end-stage HCM, prognosis was poor, with 2-year cardiovascular event-free survival rate of 71.0%. CONCLUSIONS: Progression to end-stage HCM is infrequent but associated with poor prognosis. Impaired LARS independently predicts disease progression beyond conventional markers, supporting its role in risk stratification.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (64 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7164962877
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Soongu Kwak, M Jeong, Chan Soon Park, H C Lee, Jun‐Bean Park, Seung‐Pyo Lee, Yong‐Jin Kim, Andrew Wang, Hyung‐Kwan Kim |
| Journal | European Heart Journal - Cardiovascular Imaging |
| Year | 2026 |
| DOI |
10.1093/ehjci/jeag150
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.